

## **Roger Illingworth, MD, PhD (1945–2013)**

Roger Illingworth, MD, PhD, came to Oregon Health & Science University (OHSU) in Portland, Ore. from Liverpool, England where he earned a PhD in biochemistry. His interests focused on the interaction between nutrition and the plasma lipid profile. He worked as a post-doctoral fellow in the laboratories of Drs. William and Sonja Connor. In 1973, he went to the University of Miami in the MD/PhD program, and returned to OHSU in 1977 as assistant professor in the Department of Medicine, Division of Endocrinology, Diabetes, and Clinical Nutrition.

Over the course of his career, he became one of a small elite group of thought leaders in this discipline worldwide. He was a member of the National Institutes of Health Nutrition Study section, a member of the Expert panel for the National Cholesterol Education program from its inception, a founding member of the American Board of Lipidology, and a long serving member of the Endocrine and Metabolic Disorders Advisory committee to the Food and Drug Administration.

Dr. Illingworth played a leading role in developing the LDL apheresis treatment modality and created that treatment option at OHSU. He played a central role in the early development of statin therapy for the treatment of arteriosclerosis. He was a national leader in academic medicine and contributed substantively to OHSU's academic community and reputation over 35 years.

(Source: <http://www.ohsu.edu/xd/education/schools/school-of-medicine/about/school-of-medicine-news/education-news/in-memoriam-illingworth-112013.cfm>)